Fox RJ, Coffey CS, Cudkowicz ME, et al. SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: top-line results. ECTRIMS 2017, #278.
‘Antisense’-oligonucleotide HTTRx verlaagt concentratie gemuteerd huntingtine
sep 2019 | Bewegingsstoornissen